Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.71 |
| ▸ | PARP3 | Q9Y6F1 | 11/20 | 0.71 |
| ▸ | PARP2 | Q9UGN5 | 7/20 | 0.71 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16227079 | 0.90 | PARP1 (0.68) | PARP1PARP3PARP2CYP1A1CYP2D6 | |
| SCHEMBL14976885 | 0.90 | PARP1 (0.77) | PARP1PARP3PARP2 | |
| SCHEMBL16227289 | 0.84 | PARP1 (0.67) | PARP1PARP3PARP2 | |
| SCHEMBL30417995 | 0.83 | PARP1 (1.00) | PARP1PARP3PARP2 | |
| SCHEMBL14976192 | 0.83 | PARP1 (1.00) | PARP1PARP3PARP2 | |
| SCHEMBL16227155 | 0.83 | PARP1 (0.61) | PARP1PARP3PARP2CYP1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL14977135 | 0.83 | PARP1 (0.98) | PARP1PARP3PARP2 | |
| SCHEMBL16227217 | 0.82 | PARP1 (0.67) | PARP1PARP3PARP2CYP1A1CYP2D6 | |
| SCHEMBL16227242 | 0.82 | PARP1 (0.64) | PARP1PARP3PARP2CYP1A1CYP2D6 | |
| SCHEMBL16226563 | 0.81 | PARP1 (0.67) | PARP1PARP3PARP2CYP1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788328-B1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2018-01-31 | — | — | EP | disclosed |
| US-9422243-B2 | 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. a corporation (IT) | 2016-08-23 | — | — | US | disclosed |
| US-20140336192-A1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. a corporation | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336192-A1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | PARP1, PARP2, PARP11 | PARP1 1/4885PARP3 4/4885PARP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.